tyrosine kinase
推荐文章
释义
[医]酪氨酸激酶；
英英释义
Tyrosine kinase
A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell. It functions as an "on"or "off"switch in many cellular functions.
以上来源于:Wikipedia
双语例句
Tyrosine kinases are involved in the pathogenesis of most cancers.
酪氨酸激酶参与了大部分肿瘤的发病。
Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.
苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
权威例句
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsThe fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Signal transduction by receptors with tyrosine kinase activity.
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Cell signaling by receptor tyrosine kinases: From basic concepts to clinical applications
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria...
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small ...
1. Rigel's kinase inhibitor, called fostamatinib, targets spleen tyrosine kinase, which among other functions enables the formation of the large immune-cell complexes found in autoimmune diseases.
Rigel的激酶抑制剂，称为fostamatinib，以脾酪氨酸激酶为目标。其主要功能是可以让自身免疫疾病形成大型免疫细胞复合体。
youdao
2. In many inflammatory diseases such as septic shock (9), and psoriasis (10) the change in protein tyrosine kinase activity has been shown.
在许多炎症性疾病，如感染性休克(9)，与银屑病(10)，酪氨酸蛋白激酶的活动会表现出变化。
youdao
3. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
中国的非小细胞肺癌病人中吉非替尼敏感的表皮生长因子受体酪氨酸激酶区域的突变。
youdao
4. Objective: to review the progress in the research of tyrosine kinase inhibitors in recent years.
目的：对近年来酪氨酸激酶抑制剂的研究进展作以综述。
youdao
5. Therefore, the aim of this study is to investigate the effects of genistein, a protein tyrosine kinase inhibitor, on acute and chronic inflammation in diabetic mice (induced by streptozotocin).
因此，本研究的目的是调查金雀异黄素，一种蛋白质酪氨酸激酶抑制剂，对有急性或慢性糖尿病炎症小鼠（诱导脲佐菌素）的影响。
youdao
6. The drugs work by preventing an enzyme called tyrosine kinase from launching a signaling cascade that fuels tumor cell growth.
这些药物的作用机制是阻断酪氨酸激酶启动信号级联反应，后者可以促进肿瘤细胞生长。
youdao
7. However, the involvement of tyrosine kinase either directly or through the prostaglandins and nitric oxide synthase in response to inflammation during diabetes is not completely understood.
不过，酪氨酸激酶是直接参与还是通过前列腺素和一氧化氮合酶对糖尿病炎症产生反应的，我们目前还不知道。
youdao
8. Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer?
PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用？ ？
youdao
9. Conclusions: the change of protein tyrosine kinase activity is involved in the differentiation of K562 cells induced by matrine.
结论：在苦参碱诱导K562细胞分化的过程中，涉及到蛋白酪氨酸激酶的活性改变。
youdao
10. Objective to investigate the change of insulin receptor tyrosine kinase (TK) activity in the pathogenesis of insulin resistance (IR).
目的探讨胰岛素受体酪氨酸激酶(TK)活性变化在胰岛素抵抗(IR)发生中的作用。
youdao
11. The inhibitor of VEGF receptor tyrosine kinase was introduced in detail.
详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。
youdao
12. ObjectiveTo study the abnormity and clinical value of tyrosine kinase signaling pathway in lung adenocarcinoma.
目的探讨肺腺癌患者酪氨酸激酶传导通路的异常和临床预后的关系。
youdao
13. Objective: to establish a method of detecting insulin receptor tyrosine kinase (IRTK) activity from erythrocytes.
目的：建立红细胞胰岛素受体酪氨酸蛋白激酶(IRTK)的活性测定法。
youdao
14. CONCLUSION: CD117 can be regard as the related tumor antigen of MM, and may be a valuable marker in the use of tyrosine kinase selective inhibitors, which inhibit the signal conduct to the target.
结论CD 117可作为MM的肿瘤相关抗原，也可作为靶向信号转导抑制剂酪氨酸激酶选择性抑制剂应用的有价值的标志。
youdao
15. In this paper, the quantity of insulin receptors and the receptor tyrosine kinase activity and its endogenous substrates were comparatively studied in K-562 cells before and after transformation.
对丁酸钠转化前后的人红白血病细胞林k- 562的表面胰岛素受体数量、胰岛素受体酪氨酸蛋白激酶活性及细胞内源性底物进行了研究。
youdao
16. CONCLUSION GST can block L-type calcium channel activity in guinea-pig colon smooth muscle cells via tyrosine kinase pathway.
结论GST可通过酪氨酸激酶途径抑制豚鼠结肠平滑肌l型钙通道。
youdao
17. Growth factor and tyrosine kinase mediated signaling is activated and the signaling against cell proliferation is inhibited in some extent, which show a state of system complexity.
生长因子与酪氨酸激酶介导的信号传导有不同程度的激活，而抗增殖和免疫防御的信号传导受到不同程度的抑制，表现出一种系统复杂性的状态。
youdao
18. Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂，能阻断酪氨酸蛋白激酶信号传导通路，从而促进肿瘤细胞凋亡。
youdao
19. I suspect the way this worked when the first transmembrane receptors tyrosine kinase evolved was simply to make activation contingent on phosphorylation of one receptor by the other.
当第一个逐步变化的跨膜受体酪氨酸激酶通过一个受体被另外一个受体磷酸化而轻易实现临时激活时，我怀疑这种作用方式。
youdao
20. Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.
苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
youdao
21. Objective:To explore the mutation of receptor tyrosine kinase ( RET ) gene in sporadic medullary thyroid carcinoma.
目的：研究散发型甲状腺髓样癌酪氨酸激酶受体基因（RET）的突变情况。
youdao
22. Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase (PTK).
目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。
youdao
23. Vascular epithelial growth factor binding with its receptor leads to cell proliferation and new vascular formation by tyrosine kinase pathway.
血管内皮细胞生长因子与其受体结合后通过酪氨酸激酶途径引起细胞的增殖及新生血管形成。
youdao
24. Binding of FLT3L to its cognate tyrosine kinase receptor, FLT3, activates STAT3 and STAT5 (1, 3).
FLT3L结合到与它同源的酪氨酸激酶的受体FLT3结合激活STAT3和STAT 5 (1,3)。
youdao
25. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
选择最佳的二线酪氨酸激酶抑制剂治疗伊马替尼治疗失败的慢性粒细胞白细胞患者：BCR - ABL突变状态是否真的重要？
youdao
26. The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies.
本发明提供了使用抗egfr抗体治疗抗酪氨酸激酶抑制剂的癌症的方法。
youdao
27. With the success of small-molecule tyrosine kinase inhibitors in non-small cell lung cancer, recent clinical researches have shown their activities against brain and leptomeningeal metastases.
随着小分子酪氨酸激酶抑制剂在非小细胞肺癌治疗上获得成功，陆续有其治疗非小细胞肺癌脑转移及脑膜转移的研究。
youdao
28. Objective: to study Somatic mutation of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR gene) in lung adenocarcinoma patients.
目的：探讨表皮生长因子受体(EGFR)基因酪氨酸激酶域体细胞在肺腺癌患者中突变的相关因素。
youdao
29. FLT3 Internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations are seen in 30% of AML patients (PTS) and are associated with poor survival.
30%的急性髓系白血病(aml)患者发生FLT3内部串联重复(itd)和酪氨酸激酶域(TKD)突变，而且生存预后较差。
youdao
30. FLT3 Internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations are seen in 30% of AML patients (PTS) and are associated with poor survival.
30%的急性髓系白血病(aml)患者发生FLT3内部串联重复(itd)和酪氨酸激酶域(TKD)突变，而且生存预后较差。
youdao
tyrosine kinase
